Scynexis signs licensing deal with Dechra for SCY-641
A cyclosporine derivative, SCY-641, is the first partnered compound from the Scynexis cyclophilin inhibitor platform, which includes a clinical candidate for the treatment of Hepatitis C, SCY-635. Scynexis
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.